ClinicalTrials.gg
RecruitingNCT03915418SOUTIEN-PCUpdated Jun 25, 2026

Validation of a Method of Screening for Sleep Disorders in Children With Cerebral Palsy, Using Connected Tools

An interventional study of Connected tools in Sleep Disorders, sponsored by University Hospital, Brest. Recruiting at 6 sites in France. Open to participants aged 6 Years to 15 Years. Per ClinicalTrials.gov, last updated 2026-06-25.

Sponsored by University Hospital, Brest · Not applicable, Interventional, and Diagnostic

How we know

From the registry’s dates

  • Started Jan 2021; still recruiting 5 years 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
140
Allocation
Not applicable
Ages
6 Years to 15 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 65 studies in Sleep Wake Disorders with a site in France — 22 open to participants now, 27 under way, 4 of them phase 3. Sleep Wake Disorders · France.

Planned enrollment
14th of 42
140 · median 87
Started
2021
with 3 others
No phase
29 of 65
11 open now
Primary completion
2027-02
later than 15 of 26 live
Registered
22nd of 65
by date

Among the 65 studies in Sleep Wake Disorders with a site in France, this one is the 14th largest by planned enrollment of the 42 interventional ones that give a count, is one of 4 that started in 2021, is one of 29 with no phase, reaches primary completion later than 15 of the 26 other live ones, and was the 22nd registered.

Sleep Wake Disorders

747 studies on the registry are indexed under Sleep Wake Disorders; 181 are open to participants now.

Browse Sleep Wake Disorders studies →

Open to participants now

22 of the 65 studies in Sleep Wake Disorders with a site in France are open now. Recruiting first, the newest first:

16 more — sign in →

All 22 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 114 Sleep Wake Disorders studies recruiting now, 40 (35%) set no upper age limit and 53 (46%) stop at 75 or younger; 22 take children under 18; 28 take healthy volunteers.

This study: 6 Years to 15 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 65 studies in Sleep Wake Disorders with a site in France, or all of them as a file.
02

Study summary

Cerebral palsy (CP) is the most common cause of child disability. Nearly 40% of PC children suffer from sleep disorders, which are not routinely screened. The neuro-cognitive, physical and environmental morbidity of sleep disorders should require their diagnosis and management. Limited access to the reference exam (polysomnography or PSG) delays the diagnosis and only allows screening of these disorders for a limited number of PC children. The hypothesis of our study is that connected technologies could optimize screening for sleep disorders in PC children by selecting children requiring PSG exploration and specific management.

03

Conditions studied

  • Sleep Disorders

Keywords

  • Screening
  • sleep disorders
  • children
  • cerebral palsy
  • connected tools
04

Who can participate

Ages eligible
6 Years to 15 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Boy or girl between 6 and 15 years old
  • Confirmed diagnosis of cerebral palsy
  • GMFCS class> 3
  • Parents and child agreement

Exclusion criteria

Exclusion Criteria:

  • Pharmacological treatment of sleep disorders
  • Diurnal and / or nocturnal ventilatory support
  • Difficulty understanding and / or participation
  • Subjects under 6 and over 15
  • Refusal to participate
  • Not affiliated with and not a beneficiary of a health insurance plan
05

Study design

Phase
Not applicable
Primary purpose
Diagnostic
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
140 participants (estimated)

Study arms

  • Experimental
    Connected tools

    1 night at home with connected tools only and 1 night at hospital with connected tools and PSG.

    Procedure: Connected tools

Interventions

  • ProcedureConnected tools

    At home, parents will record their child's sleep for 1night Then, on the date scheduled for the inclusion of the children and after the recording of the 1 night at home, the child will spend a night in a hospital environment to carry out the recording by polysomnography and tools connected simultaneously.

06

What researchers measure

Primary outcomes

  1. Sensitivity of the diagnosis of sleep disorder

    Sensitivity of sleep disorder diagnosis (positive / negative) obtained using connected tools in reference to that obtained by PSG

    Time frame: 15 days

  2. Specificity of the diagnosis of sleep disorder

    Specificity of sleep disorder diagnosis (positive / negative) obtained using connected tools in reference to that obtained by PSG

    Time frame: 15 days

Secondary outcomes

  1. Diagnosis

    Sensitivity and specificity of sleep disorder diagnosis using tools connected during 1 night at home (in comparaison with sleep disorder diagnosis using PSG)

    Time frame: 15 days

  2. Acceptability assessed by acceptability score for parents, and if possible children

    Acceptability assessed by the acceptability score for parents, and if possible children, obtained by the SUS "System Usability Scale" scale. This questionnaire consists of ten questions to collect the subjective point of view of the user on the systems used

    Time frame: 15 days

  3. Sleep Quality Questionnaire

    Sleep quality questionnaire used as a screening tool for sleep disorders: use of the Sleep Disturbance Scale for Children. Sleep Disturbance Scale for Children (SDSC) is a screening tool for sleep disorders in children and adolescents with good psychometric properties. It is one of the most used sleep questionnaires in the clinic but also in clinical research. Since its creation, the SDSC has been translated into several languages and recently validated in French. The ranking is obtained from a 26-item questionnaire completed by the parents. This scale distinguishes 6 major groups of sleep disorders: disorders of the installation or maintenance of sleep, breathing disorders, waking disorders, sleep-wake transition disorders, excessive daytime sleepiness and hypersudation of sleep.

    Time frame: 15 days

  4. Data quality outcome measures

    Data quality will be assessed by establishing for each sensor the ratio (expressed in percent value) between the duration of the data effectively recorded to the total duration the patient weared the sensors. Pauses in recording during recording sessions will be identified in absolute value and duration for each sensor. Specific issues in recording will be reported, especially regarding the contents of RAW files.

    Time frame: 25 months

  5. A cost analysis of the sensor screening strategy will be compared to the PSG and the quality of life

    A cost analysis of the sensor screening strategy will be compared to the PSG and the quality of life, measured as quality-adjusted life year QALY, will be simulated for one-year health conditions.

    Time frame: 25 months

07

Study locations

1 of 6 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2021 (actual). Primary completion is estimated for Feb 2027, 73 months after the start.

Of 214 non-industry interventional studies with no phase under Sleep Wake Disorders, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 40. This study's planned 73 months is above that.

Counting every sponsor, half of 249 studies reached it within 19 months; a quarter within 6 and three quarters within 37.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 7, 2018
First posted
Apr 16, 2019
StartActual
Jan 12, 2021
Primary completionEst.
Feb 2027
CompletionEst.
Feb 2027
Last update
Jun 25, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 25, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT03915418
Responsible party
Sponsor
First posted
Apr 16, 2019
Start date
Jan 12, 2021
Primary completion
Feb 2027 (estimated)
Completion
Feb 2027 (estimated)
Last update
Jun 25, 2026

Study contacts

Juliette Ropars, MD
Contact
juliette.ropars@chu-brest.fr
02 98 22 33 89 ext. +33
Juliette Ropars, MD
principal investigator · Brest University Hospital in France

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion